Form 4: Ocular Therapeutix Executive Peter Kaiser Receives Stock and Options

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, was granted 100,000 restricted stock units and options to purchase 200,000 shares of common stock.

Summary

• Peter Kaiser, the Chief Development Officer of Ocular Therapeutix, received 100,000 restricted stock units (RSUs) on October 2, 2024.
• These RSUs will vest in equal annual installments over three years, starting on October 1, 2025, contingent upon continued service to the company.
• Kaiser also received options to purchase 200,000 shares of Ocular Therapeutix common stock at an exercise price of $9.31 on October 2, 2024.
• These options vest over four years, with 1/48th of the shares vesting monthly beginning November 1, 2024, and expire on October 1, 2034.
• Following these transactions, Kaiser directly owns 215,984 shares of Ocular Therapeutix common stock and options for 200,000 shares.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of executive compensation, which is generally viewed neutrally. The grants themselves can be seen as a positive sign of confidence in the company's future, hence the slightly above-average score.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a commitment to long-term value creation at Ocular Therapeutix.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the grants as an incentive for management to improve company performance.
• Employees may see the grants as a positive sign of the company's commitment to its leadership.

Key Dates